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Summary. Purpose. The goal of this study was to
evaluate the experimental effectiveness of Regenerative
Factor Rich Plasma (RFRP) of human blood versus Fetal
Bovim Serum (FBS) and neuropeptide Substance P (SP)
on corneal epithelium cell proliferation. Method. Rabbit
corneal epithelium cell (CCL-60) growth was compared
between different RFRP fractions, FBS and with the
neuropeptide Substance P. The ability of the RFRP
fractions and SP to revert the inhibitory effect of the
CsA was also evaluated. Results. All groups showed an
increase (p<0.001) in corneal epithelial cell growth
compared with the control group. The maximum
capacity of cell growth was obtained with dilutions of
50% in the FBS, RFRP-I, RFRP -II, RFRP-III groups
and with 100nM of SP. The highest growth was observed
with 50% FBS, RFRP-I and RFRP-II. The group with
SP and RFRP-III had significantly lower growth
(p<0.001). When the NK1 receptor antagonist CsA was
added at a dose of IC50, we found a significant decrease
in cell growth (p<0.001) in all culture conditions,
including the control group. The decrease was similar in
all groups, but was especially pronounced in RFRP-II.
RFRP I, II and III promoted growth more than SFB
10%. Conclusion. The RFRP of human blood promotes
the growth of corneal epithelial cells in a significantly
more efficient manner than FSB and SP. RFRP can be
effective both in cell cultures and stem cell cultures.
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Introduction
Autologous serum has been used to treat disorders of
the corneal epithelium thanks to its antigenic effect
(Chaumeil et al., 1994; Geerling et al., 1998) and
epitheliotrophic effect (Fox et al., 1984; Tsubota et al.,
1999b), and is more effective than other non-biological
treatments (Geerling et al., 2001; You et al., 2001; Noble
et al., 2004; Kasper et al., 2008)
The efficacy of the serum depends on the plasma
concentration and the length of treatment (Tsubota et al.,
1999a; Goto et al., 2001). Serum has been used in the
development of various hemoderivates, such as platelet
concentrates (Hartwig et al., 2004), platelet-rich plasma
(PRP) (Frechette et al., 2005) or growth factor rich
plasma (GFRP) (Alio et al., 2007), which use a
particular fraction of the plasma, and whose active
principle is based on the action of platelet growth
factors. 
Particular fractions of serum and plasma accelerate
the growth, migration and differentiation of the corneal
epithelium (Hartwig et al., 2005). In addition to platelets
and growth factors, other factors such as neuropeptides
(Nakamura et al., 2003; Matsumoto et al., 2004),
fibronectin (Gordon et al., 1995), vitamin A (Nelson and
Gordon, 1992), antimicrobial proteins (Lagnado et al.,
2004), lactoferrin and immunoglobulin (Fukuda et al.,
1996) are also involved in these processes. The clinical
application of these elements in an isolated approach has
Effect of regenerative factor rich plasma, P substance
and fetal calf serum on the growth of epithelial cells in
the cornea. Comparative experimental study
R. Márquez de Aracena del Cid1,2 and A. Pérez Ordoñez3
1Department of Surgery (Ophthalmology), University of Seville, 2Clinica Centro Cid and 3Unit of Infectious Disease, Microbiology and
Preventive Medicine, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío, Seville, Spain
Histol Histopathol (2013) 28: 1065-1071
Offprint requests to: Rafael Márquez de Aracena del Cid, calle





Cellular and Molecular Biology
failed to produce positive results (Nelson and Gordon,
1992; Gordon et al 1995). For this reason, regenerative
factor rich plasma (RFRP) was chosen, since includes all
these elements and has been clinically shown to speed
up the healing of wounds and corneo-conjunctival burns
(Márquez de Aracena et al., 2007; Márquez de Aracena
and Montero, 2009), and to facilitate the adaptation of
transplants and histocompatible grafts (Márquez de
Aracena et al., 2006; Márquez de Aracena, 2012a,b).
On the other hand, Substance P (SP) has an
important effect on plasma, since it promotes migration
(Nishida et al., 1996) and mitogenesis, is involved in
platelet aggregation and plays a role in regulating
thrombus formation, and platelets have specific
receptors for SP NK1 (Graham et al., 2004). High
concentration levels of SP are needed to trigger total
platelet precipitation (Graham et al., 2004). This might
at least partially account for the clinical efficacy of the
topical and subconjunctival application of hemoderivates
like RFRP, which add no artificial substances, and lead
to gradual platelet activation when they come into
contact with the neuropeptides released by the ocular
surface. The presence of SP receptors (NK1) in platelets
might lead us to think that the potential effect of blood
derivates on the ocular surface has something to do with
the presence of this neuropeptide. 
On the other hand, in cell cultures, media such as
fetal bovine serum (Borderie et al., 1999) or umbilical
cord (Zhao et al., 2004) have been used, which present
certain technical difficulties: possible risk of
antigenicity, transmission of infectious diseases
(Geerling et al., 1998), immune rejection, clotting
disorders (Anitua et al., 2004) and excessive expense. In
this context, we might assume that other hemoderivates
like RFRP could be regarded as the appropriate medium,
above all for autologous cell cultures in which the
patient’s own blood can be used, since this is easily
available, low in cost, and will not give rise to problems
with antigens. 
For this reason, we propose to assess the
experimental efficacy of the various fractions of RFRP
in cell proliferation in the corneal epithelium, determine
what degree of involvement neuropeptides (SP) have in
this proliferative process, and evaluate the possibility of
using RFRP as a cell culture medium. 
Material and methods
Analysis was conducted using the methods cited below
1. To obtain the optimal growth concentration, rabbit
corneal epithelium cells (CCL-60) were cultured with
different fractions of RFRP and FBS at increasing
concentrations (10, 25 and 50%), and SP at 5, 10, 100
and 500 nM.
2. CCL-60 cell growth with the optimal
concentration of FBS, RFRP-I, RFRP II, RFRP-III and
SP was compared with the control group, which was
defined as the standard culture condition.
3. To calculate the maximum inhibitory
concentration of the neurokinin-1 (NK-1) receptor
antagonist Cyclosporin A (Cs-A), CCL-60 cells were
cultured with increasing concentrations of CsA (10-
50%).
4. To evaluate the ability of the RFRP to revert the
inhibitory effect of the CsA, CCL-60 cells were cultured
with RFRP-I, RFRP-II y RFRP-III and SP after the
addition of the NK-1 receptor antagonist. 
Cell line
Rabbit corneal cell line CCL-60 was purchased from
American Type Culture Collection (ATCC, Manassas,
USA). Cell cultures were maintained in Eagle’s
Minimum Essential Medium (Gibco BRL, Invitrogen
Corporation, Barcelona, Spain) supplemented with 10%
fetal bovine serum inactivated (FBS) by heat (Gibco) as
recommended by ATCC. The cells were maintained in
culture flasks of 75 cm2 (Falcon, Heidelberg, Germany)
at 37° C in a humidified atmosphere of 5% CO2 andsubcultivated by trypsinization at 5% using Trypsin-
EDTA (Sigma-Aldrich, Madrid, Spain). 
Preparation of the compounds
1. Method for obtaining the different fractions of
RFRP.
Twenty mL of male peripheral blood was extracted
by venipuncture in sterile tubes (4.5 mL per tube) with
5% sodium citrate base and then centrifuged at 2100 rpm
for 7 minutes followed, by separation of plasma red cell
with the pipette. The three fractions were defined as
follows: RFRP I: 0.5 mL immediately over the red series
rich in proliferating factors; RFRP-II: 0.5 mL over the
previous fraction rich in migratory factors RFRP- III: the
rest of the plasma that is poor in regenerative factors.
Plasma was extracted from the deepest peripheral
fraction. The RFRP fractions were stored at 4°C for 2
weeks or -4°C for around 4 months (26, 27, 28). The
number of platelets per liter was measured.
The resulting plasma contained a high concentration
of platelets and other metabolites, in such a way that the
fractions closest to the red series presented the greatest
number of platelets, growth factors and neuropeptides,
favoring cell growth, while the most distant ones, which
had fewer platelets and were richer in vitamin A and
fibronectin (Márquez de Aracena, 2012b) favored cell
migration, among other aspects (Liu et al., 2006). 
2. Preparation of the NK1 receptor antagonist,
cyclosporin A-.
The commercial preparation Neoral Sandimmum
sun 100mg/ml (Novartis) was used. Each ml of oral
solution contained 100 mg of cyclosporine
microemulsion, 94.70 mg of ethanol and 383.70 mg of
castor oil-hydrogenated polyoxyl-40. The active
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ingredient was cyclosporin A (CsA), a calcineurin
inhibitor and an NK1 receptor antagonist (MW: 1202.3).
It was diluted in bidistilled water. In order to determine a
50% inhibitory concentration (IC50), different
concentrations (10, 25 and 50 mM) were used in at least
three different assays.
3. Preparation of the NK1 receptor antagonist
substance P
The neuropeptide SP (Arg-Pro-Lys-Pro-Gln-Gln-
Phe-Phe-Gly-Leu-Met-NH2) PM 1347 acetate salt
(Sigma-Aldrich, Madrid, Spain) 25 mg vial, purity 98%
was dissolved in bidistilled water. In order to determine
cell proliferation induced by SP, different concentrations
were evaluated (5, 10, 100 and 500 nM).
Proliferation test
The cell proliferation test was performed following
the colorimetric method based on the tetrazolium
compound CellTiter 96 Aqueous one solution cell
proliferation assay (Promega Corporation, Madison, WI,
USA). Cells were cultured for 4-5 days preceding the
assay, separated by trypsin and counted in a counting
chamber of the Bürker with Trypan blue type. The cells
were seeded on 96-well plates, with a total of 104 cells
per well in a total volume of 100 mL of culture medium.
The experiments were performed using the control wells
with and without FBS and the various compounds
evaluated in the concentrations indicated in the previous
section. Once cells were added, the plates were kept in a
5% CO2 atmosphere at 37°C for 48 hours. The
absorbance, which is directly proportional to the number
of living cells, was measured at 490nm with a plate
spectrophotometer (AsysHitech UVM 340. Isogen Life
Science, Spain). The values were standardized by using
as 100% the maximum cell growth cultured in the
standard medium recommended by ATCC (10% FBS).
Each plate was performed in triplicate and all
experiments were performed a total of three times
separately. 
The research followed the tenets of the Declaration
of Helsinki; informed consent was obtained from the
subject after explanation of the nature and possible
consequences of the study, and where applicable, the
research was approved by the institutional human
experimentation committee or institutional review board
(IRB). 
Statistical analysis
Statistical analysis was performed by a post hoc
multiple comparison test (ANOVA) performing the
homogeneity test of variances using the Bonferroni or
Dunnett T3 test, and assuming a significance level of
0.05 using SPSS 16.0 for windows (SPSS, Chicago, IL.).
Results
The RFRP III had a platelet concentration of
257x109/L; RFRP II 307x109/L and RFRP I 521x109/L.
The three fractions were free of leukocytes.
All study groups showed an increase (p<0.001) in
corneal epithelial cell growth compared with the control
group (Fig. 1). The maximum capacity of cell growth
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Fig. 1. Cell l ine CCL-60 concentration
measured after the addit ion of different
increasing concentrations of FBS, SP and
platelet fractions (FIII, FII, FI). *: All groups were
significantly different compared to control
(P<0.001), and significantly different compared
two by two, except for: # 50% RFRP-III vs.
199nM SP and § 50% RFRP-II vs. 50% RFRP-
I.
was obtained with dilutions of 50% in the culture
medium in the FBS, RFRP-I, RFRP -II, RFRP-III groups
and with 100nM in the SP group. The slowest growth
was represented by FBS at 10% (Figs. 1, 2). 
The highest growth was observed with a
concentration of 50% FBS (275±7.1%), RFRP-I
(204.8±4.5%) and RFRP-II (197.5±5.8%) added to the
culture medium. Fifty percent of FBS showed an
increase with respect to RFRP-I and II. The group with
medium enriched with SP (142.5±2.2%) had lower
growth (p<0.001) than FBS50% RFRP I and RFRP -II,
with no significant differences compared with RFRP-III
(138.1±4.7%). 
When an antagonist of NK-1 receptors (Cs-A) was
added at a dose of IC50, there was a reduction (p<0.001)
in cell growth in all groups (Figs. 3, 4) including the
control group (p>0.001). RFRP-I and RFRP-II groups
also maintained their increase over the SP group
(p<0.001). The quantitative reduction caused by the CsA
in absolute terms showed no differences between any of
the groups, with an average decrease of 32.56 (C: 30.31;
SP: 34.94; RFRP-III: 26.97; RFRP-II: 45,4; RPRP-I:
25.2). The RFRP-II reduction was slightly greater
(152.09±2.2%) with respect to the other groups, and the
difference was accentuated with respect to RFRP-I
(179.58±0.6%).
The culture medium most conducive to growth was
FBS at 50%, followed by RFRP-I (50%), RFRP-II
(50%) and finally RFRP III (50%) and SP. Regarding
growth in enriched medium with SP, we found
significant differences (p<0.001) in the case of the media
supplemented with FBS 50%, RFRP-I and RFRP-II.
There were no differences compared with the medium
supplemented with RFRP-III.
When the NK1 receptor antagonist CsA was added
at doses of IC50, we found a significant cell growth
decrease (p<0.001) in all culture media, including the
control culture. The decrease was similar in all groups,
and was especially pronounced in the RFRP-II group.
However, all groups continued to maintain significant
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Fig. 3. Concentration cell l ine CCL-60
measured after the addition of: NK1 receptor
antagonist cyclosporin A (CsA) at doses of IC50
alone and with various platelet fractions (RFRP-
III, RFRP-II, RFRP-I) or the SP. All groups were
significantly different compared to control in the
group without CSA* (P<0.001) or with CsA #
(P<0.001).
Fig. 2. Cell l ine CCL-60 concentration
measured after the addition of: fetal bovine
serum (FBS), substance P (SP) and different
fractions of platelet factors: RFRP-III (FIII);
RFRP-II (FII); RFRP-I (FI). *All groups were
significantly different compared to control
(P<0.001) and significant differently compared
two by two, except for: # 50% RFRP-III vs.
100nM SP (P=0.1) and § 50% RFRP-II vs. 50%
RFRP-I (P=0.1).
growth in comparison with the control group both with
and without the NK-1 antagonist. The differences were
similar to those in the previous study with no NK1
antagonists. The RFRP-I group continued to show a
greater increase, whereas the RFRP-II group decreased
more and the RFRP-III and SP groups remained at the
same level. There were no significant differences in the
decline in growth in any of the groups treated with NK1
antagonist. It was also noted that the group cultured with
CsA and SP simultaneously had a significant increase
compared to the control group. Cell growth in the groups
treated with FIII and SP was very similar, even after
adding NK1 antagonists. There was also a further
decline in growth in the FII group compared to I and III. 
Discussion
It is known that the fractions that are richest in
platelets favor cell proliferation most, thanks to the
presence of growth factors and neuropeptides, whereas
those that are poor in platelets (and rich in vitamin A and
fibronectin) promote cell migration more (Liu et al.,
2006). The aim of treatment is to increase cell
proliferation, migration and differentiation. For this
reason, depending on the particular requirements of the
situation, the technique explained here can be used to
obtain the plasma fractions that are most useful, without
the need for adding precipitants like calcium chloride to
the GFRP (Anitua et al., 2004). 
In this study, it was noted that all groups (FBS,
RFRP and SP) experienced increased cell growth: all
showed significant growth compared to the control
group (p<0.001). Overall, they were dose-dependent,
meaning that a higher concentration produced higher
growth. One exception to this rule was SP: when
amounts over 100 nM were used, the growth was lower.
The FBS at 50% had significant growth compared to the
rest (p<0.001), followed by the RFRP-I and RFRP-II at
50% groups; SP and RFRP -III groups had a lower
growth, although it was still significant, with similar
behavior. The slowest growth, 10%, was represented by
FBS; this is a normal concentration of serum-supplement
medium (Bray et al., 2012).
These results showed that the most appropriate
culture medium to culture cells would be that enriched
with FBS, although the technical problems identified
previously have encouraged our search for alternative
means. In this sense, as a consequence of the results
obtained, hemoderivates could be considered as an
appropriate medium, especially in the case of autologous
cell cultures in which the blood of the individual favors
growth due to its zero antigenicity, decreasing the
chances of transmission of disease. 
The usefulness of RFRP was observed in all the
fractions employed here, especially in RFRP-I and
RFRP-II, while the RFRP-III group produced less
growth, as did the SP group. These data confirmed the
effectiveness of its clinical application (Márquez de
Aracena et al., 2006, 2007; Márquez de Aracena and
Montero, 2009). In our experience, RFRP’s effectiveness
has been demonstrated in treatment for postoperative
pterygium and recurrent corneal erosions. It has been
shown to shorten the healing time of post-traumatic
keratitis, promote epithelization of eyelid burns, and
improve and enhance subjective epithelization in a
diagnosis of dry eye (Márquez de Aracena, 2012b).
To evaluate an objective and real response in a
similar pattern to normal conditions, blood was obtained
from a healthy subject with an average number of
platelets. Since we found significant efficacy regarding
cell growth using different concentrations of RPRF, it
seems probable that its effectiveness would be improved
in those patients with a higher platelet concentration.
However, neuropeptides such as SP have been
shown to be an important factor in stimulating the
corneal epithelial migration (Liu et al., 2006). Given that
in some ocular surface disorders such as neurotrophic
ulcers these substances are decreased, they may be
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Fig. 4. Cell concentration of the CCL-60 line
measured after addition of the receptor NK1
Cyclosporin A (CsA) at a dose of IC50 alone
and with the different platelet fractions (FIII, FII,
FI) or SP. * P<.001 compared with control. 
** P<0.001 compared with 25µM CsA. ***
P<.001 with respect to 25µ MCsA+100n MSP.
substituted by the application of serum (Nishida et al.,
1996; Liu et al., 2006). In this study we observed that
SP, separately administered, is less effective than RFRP
hemoderivates. However, neuropeptides cannot be
disregarded, given that the addition of SP antagonist
(Cs-A) produces a reduction in all study groups in a
similar manner. So the increased growth of corneal
epithelial cells is not only due to the neuropeptide (SP),
but other pathways or factors are also involved.
Furthermore, CsA-related cell growth inhibition in the
SP group was also limited, given that it used other ways
to promote cell growth.
It was evident that the culture medium with SP acted
in a similar way to poorer plasmatic fractions (RFRP -I),
and as the plasma concentration is higher (RFRP-II and
III), the differences are more significant. Because of this,
SP enhanced cell growth on the epithelium of the cornea
to a limited extent.
CsA could be considered to be a factor which causes
an overall decline in corneal epithelial growth, which
can be situated at 32.56 in all groups. This also indicates
that it had a determined and limited mechanism of action
as well as specific inhibition.
The decrease in growth was slightly lower in the
RFRP-II group than in the rest. This fact could mean
that, in the fraction retained, a higher proportion of
certain elements could well be affected by CsA. The fact
that until now we have considered that SP receptors are
located in the platelets, with the RFRP-III fraction as the
richest one, is curious. We could perhaps deduce that the
inhibitory function of the CsA acted on cell growth in a
limited way and not just at the level of substance P and
platelets. 
The effectiveness of RFRP on corneal epithelial cell
culture led us to consider it as a suitable factor for cell
culture, especially in autologous cultures of both adult
and pluripotential cells for later grafts and transplants.
This confirms the results of our preliminary studies
(Márquez de Aracena and Pérez, 2012a,b; Márquez de
Aracena and Montero, 2012; Márquez de Aracena,
2012a,b) 
Conclusion
This study confirms the results of previous research
concerning the effectiveness of RFRP on the
regeneration of the ocular surface to promote cell
growth. 
RFRP was effective as an additive factor for culture
cell medium, especially fractions I and II. RFRP is more
effective than FBS at the usual dose.
SP promoted cell growth in a limited way, less than
RFRP did. They may therefore have different
mechanisms of action. RFRP, which is a simple,
economical, effective and ambulatory technique, can be
very useful for cell and stem cell culture, especially
autologous culture for later grafts. It can avoid potential
problems caused by using FBS or the umbilical cord
(transmission of diseases, infections and immunity).
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